Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2023 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Enters Into $150 Million Credit Facility

ROCKVILLE, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 09, 2023 18:15 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 28, 2023

ROCKVILLE, Md., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 22, 2022 17:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 08, 2022 17:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Present at Two November Healthcare Conferences

ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 08, 2022 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Third Quarter 2022 Financial Results

Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million...
October 25, 2022 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022

ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
October 10, 2022 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Provides Regulatory Update on SPN-830

ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of...
August 31, 2022 16:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Present at the 2022 Wells Fargo Healthcare Conference

ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
August 04, 2022 16:01 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Second Quarter 2022 Financial Results

Second quarter 2022 total revenues of $170.1 million, a 20% increase compared to second quarter 2021Second quarter 2022 GAAP operating earnings of $11.3 million; second quarter 2022 non-GAAP operating...
July 25, 2022 17:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...